通策医疗(600763) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 708,442,365.10, representing a year-on-year increase of 5.03%[4] - The net profit attributable to shareholders for the same period was CNY 173,215,140.31, reflecting a growth of 2.51% compared to the previous year[4] - The basic earnings per share for Q1 2024 was CNY 0.54, showing a slight increase of 1.89%[4] - Total operating revenue for Q1 2024 reached ¥708,442,365.10, an increase of 5.5% compared to ¥674,535,941.41 in Q1 2023[18] - Net profit for Q1 2024 was ¥203,927,920.68, compared to ¥197,535,406.14 in Q1 2023, representing a growth of 3.2%[19] - Earnings per share for Q1 2024 were ¥0.54, slightly up from ¥0.53 in Q1 2023[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 17.45%, amounting to CNY 129,407,477.28[4] - Cash flow from operating activities in Q1 2024 was ¥646,195,492.97, an increase from ¥615,794,420.54 in Q1 2023[21] - Total cash inflow from investment activities was $8,010,488.89, significantly lower than $164,522,177.12 in the previous period[22] - Cash outflow from investment activities totaled $157,560,127.05, compared to $211,046,930.77 in the previous period, indicating a reduction of 25.4%[22] - Net cash flow from financing activities was -$64,356,040.91, contrasting with a positive cash flow of $221,819,580.46 in the previous period[23] Assets and Liabilities - Total assets at the end of Q1 2024 reached CNY 6,091,919,301.07, a 1.43% increase from the end of the previous year[5] - The total liabilities as of Q1 2024 amounted to ¥1,759,365,241.63, down from ¥1,883,291,446.47 in the previous year[18] - The total current liabilities decreased to approximately CNY 512.56 million from CNY 644.69 million, a reduction of about 20.5%[17] - The total non-current assets reached approximately CNY 5.15 billion, up from CNY 5.04 billion, reflecting an increase of about 2.2%[17] Shareholder Equity - The equity attributable to shareholders increased by 4.50% to CNY 3,976,225,790.42 compared to the end of the previous year[5] - The total equity attributable to shareholders reached ¥3,976,225,790.42 in Q1 2024, compared to ¥3,805,042,375.87 in Q1 2023, reflecting an increase of 4.5%[18] Operational Metrics - Accounts receivable increased by 34.71%, primarily due to an increase in receivables from medical insurance and customer sales[8] - Goodwill rose by 45.31% due to the acquisition of Loudi Dental Hospital during the period[8] - The company received government subsidies amounting to CNY 2,096,628.62, which are closely related to its normal business operations[6] - The company reported an investment income of ¥12,329,246.39 in Q1 2024, compared to ¥9,093,068.14 in Q1 2023, indicating a significant increase of 35.5%[19] - Research and development expenses for Q1 2024 were ¥11,235,139.47, slightly higher than ¥11,077,832.40 in Q1 2023[19] Cash Management - The company's cash and cash equivalents decreased to approximately CNY 510.11 million from CNY 594.46 million, representing a decline of about 14.2%[16] - The ending balance of cash and cash equivalents was $509,582,218.44, down from $961,999,873.65 at the end of the previous period[23] - Cash paid for employee compensation increased to $304,031,478.13, up from $269,962,877.38, reflecting a rise of 12.6%[22] - Cash paid for taxes rose to $37,852,582.61, compared to $23,930,161.25, marking an increase of 58%[22] Accounting Standards - The company did not apply new accounting standards starting in 2024, maintaining consistency in financial reporting[24]